David Pring-Mill

TuHURA Biosciences Acquires VISTA-Inhibiting Antibody, Expanding Immuno-Oncology Pipeline

Tampa, Florida-based TuHURA Biosciences has completed its acquisition of Kineta, Inc., adding a Phase 2-ready VISTA-inhibiting monoclonal antibody to its pipeline of cancer immunotherapy treatments designed to overcome resistance mechanisms that limit current therapies. Key Points The acquisition positions TuHURA

TuHURA Biosciences Acquires VISTA-Inhibiting Antibody, Expanding Immuno-Oncology Pipeline Read More »

Principal Technologies Signs Letter of Intent to Acquire Swiss Medical Research Company for $44 Million

A Canadian healthcare acquisition company is continuing to build its portfolio of healthcare technology companies. Principal Technologies Inc. announced on December 11, 2024, that it signed a non-binding letter of intent to acquire a 70.7% controlling interest in Syndermix AG,

Principal Technologies Signs Letter of Intent to Acquire Swiss Medical Research Company for $44 Million Read More »